Title

Clinical study evaluating antihyperglycemic efficacy and safety of terminalia arjuna versus sitagliptin in Type-2 diabetes mellitus patients

Authors

Ved Prakash^1,*, Nidhi Goel², Kiran Rajendra Giri¹ & Ashish Goel³

Affiliation

¹Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh - 221005, India; ²Department of Pathology, Baba Kinaram Autonomous State Medical College, Chandauli, Uttar Pradesh, India; ³Department of Physiology, Graphic Era Institute of Medical Sciences, Dehradun, India; *Corresponding author

Email

Ved Prakash - E - mail: sonivedgmc@bhu.ac.in; headpharmaco@bhu.ac.in

Nidhi Goel - E - mail: dr.nidhigoel@gmail.com
Kiran Rajendra Giri - E - mail: drkirangiri@bhu.ac.in
Ashish Goel - E - mail: ashishgoel.geims@geu.ac.in

Article Type

Research Article

Date

Received December 1, 2024; Revised December 31, 2024; Accepted December 31, 2024, Published December 31, 2024

Abstract

Diabetes mellitus (DM) and its complications are devastating and our literature has mentioned different potentialities of Terminalia arjuna, including antihyperglycemic effects, but majority researches done on animals, rarely clinical studies conducted. Our 3month study enrolling 60 DM patients analyzed bark of T.arjuna for its antihyperglycemic effects along with safety, group TAM: Terminalia arjuna 1gm with metformin 500mg twice daily, group SGM: Sitagliptin 100mg once, with metformin 500mg twice daily. FBS, LFT and ADRs monitored at baseline, 4, 8 and 12weeks, while HbA1c at baseline and 12weeks, FBS and HbA1c showed significant (<0.05) reduction in both groups, the reduction in FBS at 4, 8 & 12weeks in gpSGM vs gpTAM (FBS -29.50±8.86 vs -22.57±9.28, -46.03±9.73 vs 42.13±8.95, -62.80±9.06 vs -61.17±10.22) and in HbA1c at 12 weeks was comparable gpSGM vs gpTAM (HbA1c -0.90±0.34 vs 0.89±0.29) difference was non-significant (>0.05). On monitoring ADRs, gpSGM 2/30 had headache and 1/30 had nasopharyngitis initially during first 4weeks, which was revealed later on, while none had any side effects in gpTAM. Thus, concluding that both are equally efficacious as antihyperglycemic agent but Terminalia Arjuna has slight upper hand as is better tolerated in respect to any adverse drug reaction with comparable efficacy too.

Keywords

Antihyperglycemic, terminalia arjuna, Type-2 diabetes mellitus

Citation

Prakash et al. Bioinformation 20(12): 1862-1868 (2024)

Edited by

P Kangueane

ISSN

0973-2063

Publisher

Biomedical Informatics

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.